CRSP

$0.00

(

+0.00%

)
Quote details

stock

Crispr Therapeutics AG

NASDAQ | CRSP

57.91

USD

+$0.00

(

+0.00%

)

At Close (As of Dec 11, 2025)

$5.44B

Market Cap

-

P/E Ratio

-5.54

EPS

$78.48

52 Week High

$30.04

52 Week Low

HEALTHCARE

Sector

CRSP Chart

Recent Chart
Price Action

CRSP Technicals

Tags:

CRSP Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$75M
Total Revenue $35M
Cost Of Revenue $110M
Costof Goods And Services Sold $110M
Operating Income -$467M
Selling General And Administrative $73M
Research And Development $321M
Operating Expenses $391M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $19M
Income Before Tax -$363M
Income Tax Expense $3.6M
Interest And Debt Expense -
Net Income From Continuing Operations -$366M
Comprehensive Income Net Of Tax -
Ebit -$467M
Ebitda -$447M
Net Income -$366M

Revenue & Profitability

CRSP Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $2.2B
Total Current Assets $1.9B
Cash And Cash Equivalents At Carrying Value $298M
Cash And Short Term Investments $298M
Inventory -
Current Net Receivables $25M
Total Non Current Assets $305M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $0
Short Term Investments $1.6B
Other Current Assets $8.3M
Other Non Current Assets -
Total Liabilities $310M
Total Current Liabilities $88M
Current Accounts Payable $15M
Deferred Revenue -
Current Debt -
Short Term Debt $17M
Total Non Current Liabilities $222M
Capital Lease Obligations $224M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $224M
Other Current Liabilities $51M
Other Non Current Liabilities $3.4M
Total Shareholder Equity $1.9B
Treasury Stock -
Retained Earnings -$1.4B
Common Stock $2.7M
Common Stock Shares Outstanding $84M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$143M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $19M
Capital Expenditures $1.9M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$280M
Cashflow From Financing $332M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$366M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$75M
Total Revenue $35M
Cost Of Revenue $110M
Costof Goods And Services Sold $110M
Operating Income -$467M
Selling General And Administrative $73M
Research And Development $321M
Operating Expenses $391M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $19M
Income Before Tax -$363M
Income Tax Expense $3.6M
Interest And Debt Expense -
Net Income From Continuing Operations -$366M
Comprehensive Income Net Of Tax -
Ebit -$467M
Ebitda -$447M
Net Income -$366M

CRSP News

CRSP Profile

Crispr Therapeutics AG Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Crispr Therapeutics AG (CRSP) is a leading gene editing company at the forefront of innovation, harnessing its proprietary CRISPR/Cas9 technology to develop transformative therapies for severe genetic disorders, including sickle cell disease and beta-thalassemia. Headquartered in Zug, Switzerland, the company is not only advancing its clinical pipeline but also establishing strategic partnerships to accelerate the development and commercialization of its groundbreaking science. With a strong commitment to enhancing patient outcomes and a solid portfolio of potential therapies, Crispr Therapeutics is well-positioned to redefine the future of medicine and play a pivotal role in the biopharmaceutical landscape.

LPTX
+368.57%
$2.05
ATPC
+39.85%
$0.09
WOK
-96.58%
$0.19
PAVS
-13.15%
$0.03
VHAI
+33.33%
$0.00
PETS
+72.05%
$3.04
NVDA
-3.51%
$177.32
F
+2.52%
$13.41
AXDX
-61.36%
$0.03
VIVK
+8.35%
$0.07
KIND
+25.87%
$2.53
RZLT
-89.48%
$1.15
ADAP
-15.14%
$0.05
DNN
-1.82%
$2.69
ORCL
-14.24%
$191.24
NXDR
+24.50%
$3.15
K
-0.01%
$83.44
SOND
-23.45%
$0.12
BTTC
+98.79%
$6.59
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
HBAN
+3.35%
$17.56
SRM
+53.27%
$10.30
IRBT
-3.43%
$5.05
WULF
+1.09%
$15.76
IVP
-23.16%
$0.06
MTSR
-0.35%
$70.50
CRWV
-2.75%
$88.16
SIDU
+41.97%
$1.13
MIGI
+30.74%
$8.76
NCLH
+2.77%
$19.24
BLNK
-6.08%
$0.94
PCG
+0.60%
$15.08
WRBY
+27.34%
$29.57
TSLA
-2.09%
$442.00
AFMD
-34.94%
$0.18
LYFT
-6.70%
$20.32
ONDS
+0.36%
$8.35
WFC
+2.02%
$90.69
CHWY
+1.52%
$35.37
MSTR
-2.30%
$184.64
AMC
-3.07%
$2.21
RDW
+2.60%
$7.48
GRYP
-10.38%
$1.38
ASST
-7.42%
$0.92
MODV
-25.22%
$0.43
RIVN
-5.59%
$16.52
APLD
-5.43%
$30.99
BNKK
-21.08%
$0.11
YGMZ
-18.12%
$0.05
PEP
+3.49%
$149.70
TWOH
-7.14%
$0.00
BMNU
-9.77%
$10.25
CCL
+3.01%
$26.28
FCX
+3.68%
$46.45
CPNG
-3.23%
$26.06
ACIU
+6.45%
$2.97
BMNR
-4.67%
$38.51
AUR
-2.38%
$4.50
CARR
+1.05%
$53.40
FUBO
-3.81%
$2.77
PLTR
-2.28%
$183.62
NGD
+0.38%
$7.83
INTC
-2.50%
$39.75
RGTI
-4.05%
$25.05
PLTD
+2.37%
$6.46
NFLX
+1.70%
$94.29
IONQ
-5.08%
$51.67
RIOT
+0.38%
$15.57
CVS
+0.93%
$78.97
CDE
-0.62%
$15.97
GM
+4.71%
$80.80
SHOT
-74.37%
$0.39
HLN
+1.61%
$9.46
NVTS
-0.54%
$9.12
ZAPP
-46.30%
$0.15
EOSE
-1.07%
$14.79
AIG
+6.09%
$81.08
CIFR
-4.43%
$17.66
IREN
-5.63%
$41.44
HOOD
-7.08%
$126.04
CAN
-5.43%
$0.88
RKLB
+4.23%
$59.95
BULL
-2.14%
$10.03
NOK
+3.13%
$6.41
ET
-1.31%
$16.45
DRCT
-8.29%
$0.08
NWL
+5.21%
$3.83
AMD
-3.61%
$213.41
BMY
+1.10%
$51.21
HPQ
+0.43%
$25.49
RR
+0.36%
$4.16
NVVE
-7.33%
$0.16
DAL
+3.73%
$69.93
JZXN
+2.11%
$0.14
IQ
+1.47%
$2.06
STLA
+3.76%
$12.12
AAPL
-0.88%
$276.30
QBTS
-1.02%
$26.52
LPTX
+368.57%
$2.05
ATPC
+39.85%
$0.09
WOK
-96.58%
$0.19
PAVS
-13.15%
$0.03
VHAI
+33.33%
$0.00
PETS
+72.05%
$3.04
NVDA
-3.51%
$177.32
F
+2.52%
$13.41
AXDX
-61.36%
$0.03
VIVK
+8.35%
$0.07
KIND
+25.87%
$2.53
RZLT
-89.48%
$1.15
ADAP
-15.14%
$0.05
DNN
-1.82%
$2.69
ORCL
-14.24%
$191.24
NXDR
+24.50%
$3.15
K
-0.01%
$83.44
SOND
-23.45%
$0.12
BTTC
+98.79%
$6.59
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
HBAN
+3.35%
$17.56
SRM
+53.27%
$10.30
IRBT
-3.43%
$5.05
WULF
+1.09%
$15.76
IVP
-23.16%
$0.06
MTSR
-0.35%
$70.50
CRWV
-2.75%
$88.16
SIDU
+41.97%
$1.13
MIGI
+30.74%
$8.76
NCLH
+2.77%
$19.24
BLNK
-6.08%
$0.94
PCG
+0.60%
$15.08
WRBY
+27.34%
$29.57
TSLA
-2.09%
$442.00
AFMD
-34.94%
$0.18
LYFT
-6.70%
$20.32
ONDS
+0.36%
$8.35
WFC
+2.02%
$90.69
CHWY
+1.52%
$35.37
MSTR
-2.30%
$184.64
AMC
-3.07%
$2.21
RDW
+2.60%
$7.48
GRYP
-10.38%
$1.38
ASST
-7.42%
$0.92
MODV
-25.22%
$0.43
RIVN
-5.59%
$16.52
APLD
-5.43%
$30.99
BNKK
-21.08%
$0.11
YGMZ
-18.12%
$0.05
PEP
+3.49%
$149.70
TWOH
-7.14%
$0.00
BMNU
-9.77%
$10.25
CCL
+3.01%
$26.28
FCX
+3.68%
$46.45
CPNG
-3.23%
$26.06
ACIU
+6.45%
$2.97
BMNR
-4.67%
$38.51
AUR
-2.38%
$4.50
CARR
+1.05%
$53.40
FUBO
-3.81%
$2.77
PLTR
-2.28%
$183.62
NGD
+0.38%
$7.83
INTC
-2.50%
$39.75
RGTI
-4.05%
$25.05
PLTD
+2.37%
$6.46
NFLX
+1.70%
$94.29
IONQ
-5.08%
$51.67
RIOT
+0.38%
$15.57
CVS
+0.93%
$78.97
CDE
-0.62%
$15.97
GM
+4.71%
$80.80
SHOT
-74.37%
$0.39
HLN
+1.61%
$9.46
NVTS
-0.54%
$9.12
ZAPP
-46.30%
$0.15
EOSE
-1.07%
$14.79
AIG
+6.09%
$81.08
CIFR
-4.43%
$17.66
IREN
-5.63%
$41.44
HOOD
-7.08%
$126.04
CAN
-5.43%
$0.88
RKLB
+4.23%
$59.95
BULL
-2.14%
$10.03
NOK
+3.13%
$6.41
ET
-1.31%
$16.45
DRCT
-8.29%
$0.08
NWL
+5.21%
$3.83
AMD
-3.61%
$213.41
BMY
+1.10%
$51.21
HPQ
+0.43%
$25.49
RR
+0.36%
$4.16
NVVE
-7.33%
$0.16
DAL
+3.73%
$69.93
JZXN
+2.11%
$0.14
IQ
+1.47%
$2.06
STLA
+3.76%
$12.12
AAPL
-0.88%
$276.30
QBTS
-1.02%
$26.52

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.